- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05606159
Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Tolerability and Effect of Bacillus Velezensis DSM 33864 on the Reduction of Risk of Recurrent Clostridioides Difficile Infection (rCDI) in Adults With a History of rCDI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The goal of this multi-center randomized double-blinded placebo-controlled trial is to evaluate the tolerability and effect of a probiotic dietary supplement on the reduction of the risk of recurrent C. difficile infection in adults who have experienced two previous C. difficile infection episodes.
The main aim of this study is to assess the effect of a probiotic dietary supplement on the colonization (cell counts) of C. difficile over time and also to assess the correlation between level of C. difficile colonization and recurrence of CDI.
Approximately, 104 research subjects will be randomized into two arms and will use either one capsule daily of the probiotic supplement or placebo once daily with breakfast, for 8 weeks. All outcomes will be compared across the supplementation and placebo arm.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Victoria Oyedokun, PhD
- Phone Number: +491723244702
- Email: vtoy@novozymes.com
Study Contact Backup
- Name: Caterina Holz, PhD
- Phone Number: +49 30921076554
- Email: caho@novozymes.com
Study Locations
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- Beaumont Hospital
-
Contact:
- Matthew Sims, PhD
-
Contact:
- Maureen Cooney
- Phone Number: 248-551-0099
- Email: maureen.cooney@beaumont.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females ≥ 18 years old
- Medical record documentation of second or subsequent recurrent CDI episode, and received standard-of-care oral antibiotic therapy completed no more than 5 days prior date of enrollment.
- Able to provide signed and dated informed consent or assent
- Able to provide blood and fecal specimens
Exclusion Criteria:
- Current episode of CDI or delayed symptom resolution from previous reoccurrence (second episode), according to the physical exam and investigator assessment
- Pregnancy or breastfeeding
- Subjects presenting with active diarrhea (3 or more stools per 24-hour period) and within Bristol stool scale range of 5-7
- Taking dietary supplement or therapeutic intervention which could significantly affect parameter(s) followed during the study (fibers, probiotics, prebiotics, symbiotic) according to the investigator or stopped in a too short period before the V1 visit (< 4 weeks)
- Previous reaction, including anaphylaxis, to any substance in composition of the study product
- Active, non-controlled intestinal disease such as Crohn's Disease, ulcerative colitis; celiac disease, or other chronic diarrheal illness
- Patients with active Pancreatitis
- Ostomized subjects, parenteral nutrition users
- Under immunosuppressive therapy or any health condition causing immunosuppression (including active hematological malignancies, acquired immune deficiency syndrome (AIDS), recent solid organ transplant (within 90 days),under treatment for rejection
- For women: Non menopausal with the same reliable contraception since at least 3 cycles before the beginning of the study and agreeing to keep it during the entire duration of the study or menopausal without or with hormone replacement therapy (estrogenic replacement therapy begun from less than 3 months excluded);
- Pregnant or lactating women or intending to become pregnant within 3 months ahead
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo control group
A placebo capsule containing microcrystalline cellulose will be taken orally, once a day, for 8 weeks.
|
1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
|
Experimental: Bacillus velezensis DSM 33864
This arm will receive a single strain probiotic capsule containing Bacillus velezensis DSM 33864. The probiotic will be taken orally, once a day, for 8 weeks. |
1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C. difficile colonization
Time Frame: 8 weeks
|
Change in colonization (counts) of toxigenic C. difficile from baseline to 8 weeks determined by quantitative PCR
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C. difficile colonization
Time Frame: 4 weeks
|
Change in colonization (counts) of toxigenic C. difficile determined by quantitative PCR
|
4 weeks
|
C.difficile colonization
Time Frame: 12 weeks
|
Change in colonization (counts) of toxigenic C.difficile determined by quantitative PCR
|
12 weeks
|
Presence and levels of C. difficile toxin in fecal samples
Time Frame: 12 weeks
|
Change in concentration of C. difficile Toxin A or B levels in fecal samples from baseline to week 4, week 8 and week 12 determined by enzyme immune assay method (EIA)
|
12 weeks
|
Quality of life assessment
Time Frame: 12 weeks
|
Change in average health-related quality of life scores at baseline, week 8 and 12, determined by EQ-5D-5L questionnaire
|
12 weeks
|
Reduction of the risk of rCDI
Time Frame: 8 weeks
|
Incidence of rCDI defined as an episode of diarrhea onset described by three or more unformed stools per 24 h as measured by the Bristol stool chart (types 5 to 7), and positive toxin assay result for C. difficile.
|
8 weeks
|
Reduction of the risk of rCDI
Time Frame: 4 weeks
|
Incidence of rCDI defined as an episode of diarrhea onset described by three or more unformed stools per 24 h as measured by the Bristol stool chart (types 5 to 7), and positive toxin assay result for C. difficile.
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: 12 weeks
|
Incidence of adverse events from baseline to 12 weeks
|
12 weeks
|
Changes in hemoglobin concentration
Time Frame: 12 weeks
|
Changes in hemoglobin concentration from baseline to 12 weeks determined by standard Full Blood Count (FBC) test
|
12 weeks
|
Changes in blood platelet levels
Time Frame: 12 weeks
|
Changes in blood platelet levels from baseline to 12 weeks determined by standard Full Blood Count (FBC) test
|
12 weeks
|
Changes in blood C-reactive protein (CRP) levels
Time Frame: 12 weeks
|
Changes in C-reactive levels from baseline to 12 weeks determined by standard blood CRP test
|
12 weeks
|
Changes in blood glucose levels
Time Frame: 12 weeks
|
Changes in blood glucose from baseline to 12 weeks determined by standard blood chemistry panel test
|
12 weeks
|
Changes in blood urea nitrogen (BUN) levels
Time Frame: 12 weeks
|
Changes in blood urea nitrogen levels from baseline to 12 weeks determined by standard blood chemistry panel test
|
12 weeks
|
Changes in blood creatinine levels
Time Frame: 12 weeks
|
Changes in blood creatinine levels from baseline to 12 weeks determined by standard blood chemistry panel test
|
12 weeks
|
Changes in blood calcium levels
Time Frame: 12 weeks
|
Changes in blood calcium levels from baseline to 12 weeks determined by standard blood chemistry panel test
|
12 weeks
|
Incidence of any diarrhea determined by the Bristol Stool Scale (score range 5-7)
Time Frame: 12 weeks
|
Incidence of any diarrhea determined by the Bristol Stool Scale (score range 5-7)
|
12 weeks
|
Incidence of gastrointestinal pain or discomfort determined by GSRS questionnaire
Time Frame: 12 weeks
|
Incidence of gastrointestinal pain or discomfort determined by GSRS questionnaire
|
12 weeks
|
Change in intestinal bile acid levels
Time Frame: 12 weeks
|
Change in bile acids assessed from fecal samples by UPLC-MS
|
12 weeks
|
Change in intestinal short-chain fatty-acid levels
Time Frame: 12 weeks
|
Change in short chain fatty acids assessed from fecal samples by GC-MS
|
12 weeks
|
Recovery rate of Bacillus velezensis assessed from fecal samples
Time Frame: 12 weeks
|
Recovery rate of probiotic Bacillus velezensis DSM33864 in fecal samples, determined by qPCR method
|
12 weeks
|
Intestinal microbiome diversity including functional and resistome genes
Time Frame: 8 weeks
|
Change in intestinal microbiome composition assessed from fecal samples using Deep Shotgun sequencing method
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew Sims, PhD, Beaumont Hospital, Royal Oak. Michigan
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NZ-GHCD-2021-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile Infection Recurrence
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
The Cooper Health SystemUnknownClostridium Difficile Infection Recurrence
-
Ferring PharmaceuticalsRecruiting
-
University of Illinois at ChicagoMerck Sharp & Dohme LLCCompletedClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceUnited States
-
Finch Research and Development LLC.CompletedClostridium Difficile Infection RecurrenceCanada, United States
-
University of Kansas Medical CenterMerck Sharp & Dohme LLCCompletedClostridium Difficile Infection RecurrenceUnited States
-
Krunal PatelRecruitingClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceUnited States
-
University of Wisconsin, MadisonNational Institute of Allergy and Infectious Diseases (NIAID)CompletedClostridium Difficile Infection RecurrenceUnited States
-
Immuron Ltd.TerminatedClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceIsrael